Secondary Logo

Welcome to Cardiovascular Endocrinology

Krentz, Andrew J.

Cardiovascular Endocrinology & Metabolism: March 2012 - Volume 1 - Issue 1 - p 1
doi: 10.1097/XCE.0b013e3283536bf6

Profil Institute for Clinical Research, San Diego, USA; Bedfordshire & Hertfordshire Postgraduate Medical School, UK.

Correspondence to Andrew J. Krentz, MD, FRCP, Profil Institute for Clinical Research, 855 3rd Ave, Suite 4400, Chula Vista, CA 91911, USA E-mail:

Received March 1, 2012

Accepted March 1, 2012



Endocrinologists can justly claim to have made many significant contributions to our knowledge of the pathogenesis and treatment of vascular disease. Classic examples that spring to mind include the hypertension of corticosteroid excess, the cardiovascular implications of thyroid hormone hypersecretion or deficiency, and characterization of the heightened vascular risk associated with diabetes mellitus. These achievements, along with numerous other examples, provide the inspiration for Cardiovascular Endocrinology – a new peer-reviewed journal for clinicians and scientists.

Important strides have been made in our understanding of the pathogenesis of vascular disease in recent years. These advances have been accompanied by the discovery of hormones and cytokines whose importance to metabolic regulation and implications for vascular disease has rapidly become apparent. Light has also been cast on novel pathways, obesity-associated inflammation for example, that may mediate some of the adverse vascular effects of common endocrine disorders. The emergence of genomics, proteomics, transcriptomics, and metabolomics as powerful new research tools augurs well for continued progress. However, the complex adverse cardiovascular effects of thiazolidinediones provide a stark reminder of how the manipulation of intermediary metabolism may not always have predictable consequences for vascular biology. Similarly, the wisdom of sex steroid replacement therapy for the prevention of cardiovascular events has come under close scrutiny in the light of clinical trial data.

Opportunities for productive collaboration between those working in endocrinology and cardiovascular medicine have never been greater. With a global explosion of obesity-associated diabetes, hypertension and dyslipidemia upon us, the need for effective collaboration to stem the threatened tide of vascular disease is clear. Accordingly, we believe that the time is right for a journal focused on bringing these specialties together. Cardiovascular Endocrinology aspires to be a valuable resource for the vascular and endocrinology clinical and research communities. Our aim is to create a forum that facilitates the exchange of information and ideas across these disciplines. To this end it is envisioned that state-of-the art reviews and editorials will feature prominently. In addition, invited expert commentaries will position original papers within the existing wider literature for readers whose primary interests may lie in another discipline. In this launch issue Jens Peter Goetze offers a personal opinion of how the term ‘cardiovascular endocrinology’ might be defined. Others may wish to contribute their own definitions. Opportunities for authors to explore areas of scientific or clinical controversy and to offer their hypotheses will be available.

Submissions are invited on all aspects of vascular–endocrine associations. Particularly welcome are studies that illuminate the mechanisms responsible for physiological and pathological interactions between hormones and the vasculature. Papers that assist the translation of research finding from the bench to clinical practice, such as, novel biomarkers and new therapies, are also warmly encouraged.

On behalf of the editorial board I invite you to share your research findings and clinical experiences with a readership united by a shared interest in endocrinology and vascular medicine. Let us know your thoughts as we progress; feedback from authors and readers will inform the journal’s development. Also, please encourage junior members of your practice or laboratory to become involved in the peer review process.

We hope that you enjoy Cardiovascular Endocrinology and will consider actively contributing to its success.

Back to Top | Article Outline


Conflicts of interest

None declared.

© 2012Wolters Kluwer Health Lippincott Williams Wilkins